活动性肝癌而非非活动性肝癌降低丙肝治愈率
基于REAL-C登记研究,纳入6081例接受无干扰素直接抗病毒药物治疗的丙肝患者,经倾向评分匹配后比较肝癌与非肝癌患者疗效。
要点
- 活动性肝癌患者DAA治疗SVR率低于非活动性肝癌。
- 活动性肝癌独立预测较低SVR,非活动性肝癌则无此关联。
- 活动性肝癌患者总体治愈率仍达85%左右。
核心结论
- 活动性肝癌而非非活动性肝癌与DAA治疗后较低SVR独立相关,但活动性肝癌患者治愈率仍相对较高(85%)。
研究设计与样本
- 采用倾向评分匹配(1:1)匹配年龄、性别、肝硬化、既往治疗、HCV基因型、治疗方案、基线血小板计数、HCV RNA、总胆红素、丙氨酸氨基转移酶和 albumin 水平,得到436对匹配患者。
主要发现
- 匹配后肝癌与非肝癌组总体SVR率分别为92.7%和95.0%,差异无统计学意义。
- 肝癌组与非肝癌组治疗中断率、不良反应和死亡率相似。
临床怎么用
- 对活动性肝癌患者接受DAA治疗时,应预期SVR率可能较低但仍较高,需个体化评估与监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cure rates of hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) for patients with active and inactive hepatocellular carcinoma (HCC) may differ, but well-controlled studies are limited. We aimed to evaluate DAA outcomes in a large East Asian HCV/HCC population compared with HCV/non-HCC patients. METHODS: Using data from the Real-World Evidence from the Asia Liver Consortium (REAL-C) registry (Hong Kong, Japan, South Korea, and Taiwan), we used propensity score matching (PSM) to match HCC and non-HCC (1:1) groups for age, sex, cirrhosis, prior treatment, HCV genotype, treatment regimen, baseline platelet count, HCV RNA, total bilirubin, alanine aminotransferase, and albumin levels to evaluate DAA treatment outcomes in a large population of HCV/HCC compared with HCV/non-HCC patients. RESULTS: We included 6081 patients (HCC, n = 465; non-HCC, n = 5 616) treated with interferon-free DAAs. PSM of the entire study population yielded 436 matched pairs with similar baseline characteristics. There was no statistically significant difference in the overall SVR rate of HCC (92.7%) and non-HCC (95.0%) groups. Rates of treatment discontinuation, adverse effects, and death were also similar between HCC and non-HCC groups. Among patients with HCC, those with active HCC had a lower SVR than inactive HCC cases (85.5% vs 93.7%; P = .03). On multivariable analysis, active HCC, but not inactive HCC, was significantly associated with lower SVR (OR, 0.28; P = .01) when compared with non-HCC. CONCLUSIONS: Active HCC but not inactive HCC was independently associated with lower SVR compared with non-HCC patients undergoing DAA therapy, although cure rate was still relatively high (85%) in active HCC patients.
引用
- Ogawa E, Toyoda H, Iio E, et al. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clin Infect Dis. 2020. PMID: 31777940. doi:10.1093/cid/ciz1160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。